Abano Terme

Researchers are evaluating a new method to assess the quality of lymph node removal during minimally invasive surgery for gastric cancer. This observational study focuses on the PhotoNodes Score, a tool designed to rate the adequacy of D2 lymphadenectomy by examining intraoperative images taken during surgery. The goal is to find a more reliable way to measure surgical quality that may also predict patient survival. During surgery, five high-quality laparoscopic or robotic images are captured at the end of the lymphadenectomy phase before reconstruction begins. Three surgeons independently review these images and score eight specific lymph node stations from poor to excellent. These scores are averaged to create a total PhotoNodes Score for each patient, reflecting the thoroughness of the lymph node removal. Participants undergo minimally invasive gastrectomy with D2 lymphadenectomy and have their surgical images collected and reviewed. Researchers will measure agreement between observers on the scoring and examine how the score relates to disease-free survival and overall survival at 1 and 3 years. Follow-up includes medical chart reviews every six months for up to three years after enrollment ends, allowing detailed assessment of long-term outcomes and surgical quality.

This research aims to study patients of childbearing age undergoing laparoscopic surgery for early-stage benign or malignant gynecological conditions. It focuses on evaluating the use of ultrasound to identify superficial endometriosis specifically in the uterosacral ligaments LUS area of the pelvis. The study is observational and does not alter the standard care these patients receive. Participants will have a level II gynecological ultrasound using a transvaginal approach to measure the thickness of the uterosacral ligaments at three points, including the median area near the uterine torus and points 1.5 cm to the right and left. These ultrasound measurements will then be compared to findings during laparoscopic surgery, which will document the presence or absence of superficial endometriosis lesions in the LUS and other pelvic locations. During the study, patients will undergo ultrasound scans and laparoscopic surgery as part of their usual care. Researchers will archive ultrasound images and compare them with surgical findings to assess how well ultrasound thickness measurements correspond to laparoscopically confirmed superficial endometriosis. The main outcomes include measuring LUS thickness and evaluating diagnostic performance parameters over about one year. The study provides detailed imaging and surgical data to improve understanding of ultrasounds role in detecting endometriosis.

This research investigates patients with newly diagnosed oligometastatic prostate cancer OMPCa who meet the CHAARTED criteria for low metastatic volume disease. The study aims to collect data in a registry from major urological centers in the Triveneto region to evaluate how local treatments, such as surgery or radiotherapy of the primary tumor, combined with systemic hormonal therapies, affect cancer outcomes and quality of life. Patients with high volume metastatic disease, defined by specific bone and visceral metastases criteria, are excluded from this study. The study is observational and involves patients receiving local treatment for their primary prostate cancer along with systemic hormonal therapy, which may be androgen deprivation therapy ADT alone or combined with other agents like Docetaxel or androgen receptor signal inhibitors ARTA. Participants will be followed to observe outcomes without randomization or comparison groups since this is a single-arm study. Participants will be monitored for overall survival, cancer-specific survival, progression to castration-resistant prostate cancer, radiological progression, quality of life, as well as treatment complications for up to three years. Data collection includes clinical assessments and quality of life evaluations from the start of treatment through follow-up. The study helps track how these treatments impact patients over time in routine clinical practice.

Researchers are evaluating the safety and clinical performance of the Oscar Peripheral Multifunctional Catheter in patients with peripheral arterial disease affecting the femoral, popliteal, and infrapopliteal arteries. This prospective, multicenter, observational study aims to confirm procedural success and monitor in-hospital complications such as vessel perforation, rupture, acute occlusion, and distal embolization. The study includes patients with significant artery narrowing and specific lesion characteristics, who require endovascular intervention. The study uses the Oscar Peripheral Multifunctional Catheter, which includes three components the Oscar Support Catheter with integrated Lock Grip, the Oscar Dilator, and the Oscar PTA Balloon. The device is used to dilate lesions in the target arteries. The study focuses on procedural outcomes such as successful crossing of the target lesion, residual stenosis after vessel preparation, and absence of procedural complications. Treatments of inflow lesions may be performed before the target lesion treatment according to local standards. Participants will undergo the index procedure where procedural success and complications are closely monitored. Assessments include measuring procedural success rates, rates of adverse device effects, distal embolization, vessel rupture, perforation, and acute occlusion, as well as flow-limiting dissections and amputation occurrences within 30 days. Data on residual stenosis and crossing success will be collected. The study period extends until January 2026, with follow-up evaluations up to 30 days after discharge.

Researchers are evaluating the management of acute and chronic osteomyelitis in patients with diabetic foot syndrome, focusing on infections localized in the forefoot. This prospective multicenter randomized trial compares the effectiveness and safety of a bioactive glass device S53P4 against standard surgical care practices. The goal is to assess healing rates and other outcomes related to bone infection treatment in specialized centers. Participants are randomly assigned to one of two groups. Group A receives surgical removal of the infected bone and soft tissue debridement, along with systemic antibiotics and optional bone substitutes except bioactive glasses. Group B undergoes similar debridement but preserves the bone cortex while replacing infected soft bone with the S53P4 bioactive glass according to its approved use. Both groups aim for primary wound closure and may have vacuum drainage placed postoperatively. Participants are followed closely after surgery with biweekly visits up to three months or until healing, and then at six and twelve months. Assessments include wound evaluation, x-rays, histopathology, laboratory tests, and quality of life and foot function questionnaires. Researchers monitor healing progression, complications such as reinfection, recurrence rates, and functional recovery. The primary outcome is the healing rate at six months, with additional measures including antibiotic duration, re-interventions, amputations, and surgery characteristics.